Astigmatism: definition and measurement

Article

Dr N. Alpins from Australia explains.

OTEurope will be bringing you a report on Dr Alpins's presentation at a later date. In the meantime further breaking news from the congress included:

Positive pooled results confirm Microplasmin’s potential to transform the treatment of retinal disorders

The pooled results from the microplasmin MIVI-TRUST Phase III programme have shown that microplasmin was successful in resolving vitreomacular adhesion (VMA) and was able to cure full thickness macular hole (FTMH) without the need for surgery. It was also reported as being safe and well tolerated.

The MIVI-TRUST programme is the largest interventional clinical programme ever performed to specifically evaluate the vitreoretinal interface in patients with retinal disorders, recruiting a total of 652 patients at 90 centres across the US and Europe.

The results were presented at the EURETINA (European Society of Retina Specialists) Congress in Paris, France by Professor Peter Stalmans (University Hospitals Leuven, Belgium). Thrombogenics, the biopharmaceutical developer of microplasmin said that the results demonstrate the potential of microplasmin to transform the treatment of a range of retinal disorders.

Both the TG-MV-006 and TG-MV-007 trials met the primary endpoint, achieving a statistically significant improvement in the resolution of VMA. The pooled results from the MIVI-TRUST program showed that 26.4% of the 465 microplasmin treated patients achieved resolution of their VMA at 28 days, compared to 10.2% of the 182 patients who received a placebo injection, a highly statistically significant result (p=0.000002).

Professor Peter Stalmans said: “I am delighted to have presented these pooled results for the first time. Based on these exciting Phase III results and my own personal experience, I have little doubt that microplasmin will quickly become an important treatment option for patients with a range of retinal disorders, including macular hole. The benefits of this simple one-off injection are very appealing, when compared to surgery, to both patients and retina specialists.”

A more comprehensive report on these results will appear in the November issue of Ophthalmology Times Europe.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences

All rights reserved.